H.C. Wainwright维持Entrada股票买入评级，目标价20美元
周二，H.C. Wainwright维持对Entrada Therapeutics股票的买入评级，目标价为USD 20.00。这家市值4.76亿美元的生物科技公司目前市盈率为12.79，估值具有吸引力，并且收到了重要的监管消息。该公司分析师Boobalan ...
FierceBiotech21 小时
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular ...
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Entrada Therapeutics Inc (TRDA) Receives a Buy from Roth MKM
In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), ...